Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962256 | 1.00 | KMT2A (0.60) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL10341246 | 0.82 | KMT2A (0.62) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| Ethane SCHEMBL7561091 | 0.82 | KMT2A (0.54) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL10310295 | 0.81 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL862990 | 0.81 | KMT2A (0.60) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL30223355 | 0.81 | SMN1; SMN2 (0.64) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL30223215 | 0.81 | SMN1; SMN2 (0.64) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL4812101 | 0.81 | SMN1; SMN2 (0.64) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL29484164 | 0.80 | ALDH1A1 (0.61) | KMT2ASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL13973608 | 0.77 | KMT2A (0.64) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101925300-A | Novel compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB | 2010-12-22 | — | — | CN | disclosed |
| WO-2010068171-A1 | A PROCESS FOR THE PREPARATION OF 3- [ (2R) TETRAHYDROFURAN-2- YLMETHYL] -2-THIOXO-L, 2, 3, 7-TETRAHYDRO-6H-PURIN-6-ONE | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068171-A1 | A PROCESS FOR THE PREPARATION OF 3- [ (2R) TETRAHYDROFURAN-2- YLMETHYL] -2-THIOXO-L, 2, 3, 7-TETRAHYDRO-6H-PURIN-6-ONE | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | KMT2A 1378/4885SMN1; SMN2 2433/4885USP2 3596/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | KMT2A 1609/4885SMN1; SMN2 2336/4885USP2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.